Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Codon Capital
BioCentury | Dec 5, 2023
Product Development
Dec. 4 Quick Takes: EyePoint’s data for Eylea competitor drive big gain
Plus: Seismic adds $121M in series B round and updates from Merck KGaA, Abbisko, Perpetual Medicines, CRISPR Therapeutics and YolTech
BioCentury | Sep 20, 2023
Finance
Sept. 19 Quick Takes: RNA editing company Airna emerges with $30M round led by Arch
Plus: Longevity-focused VC debuts and updates from Recode, Merck, Taysha and Paratek
BioCentury | Jul 21, 2023
Management Tracks
Ann Lee-Karlon named CEO of EpiBiologics
Plus: Haas becomes CEO at LimmaTech, and updates from Sagimet, Agenus, Triumvira and Passage Bio
BioCentury | Nov 15, 2022
Finance
Nov. 15 Quick Takes: Panacea to deploy $276M in pair of funds
Plus: Acrivon’s IPO; fundings for Bonum, CG Oncology and Jnana; and pipeline updates from Arcutis and Everest
BioCentury | Apr 12, 2022
Emerging Company Profile
Ansa debuts with $68M series A for enzymatic DNA synthesis, hold the blocking groups
By using enzyme-cleavable linkers instead of blocking groups, Ansa can generate long, undamaged DNA molecules
BioCentury | Aug 13, 2020
Finance
Codon adds Roche Venture’s Mutz to team to capitalize therapeutic, synthetic bio start-ups
Codon Capital looks to grow early-stage investments, newco formation with addition of Partner Mutz
Items per page:
1 - 7 of 7